Biological Assembly 1  

 3D View: Structure | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 19426.56 
• Atom Count: 1310 
• Residue Count: 170 
• Unique protein chains: 1

1MMR

MATRILYSIN COMPLEXED WITH SULFODIIMINE INHIBITOR

• DOI: 10.2210/pdb1MMR/pdb

• Classification: METALLOPROTEASE
• Organism(s): Homo sapiens
• Expression System: Cricetulus griseus


• Deposited: 1995-03-22 Released: 1996-04-03 
• Deposition Author(s): Browner, M.F., Smith, W.W., Castelhano, A.L.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.4 Å
• R-Value Work: 0.187 

Literature

Matrilysin-inhibitor complexes: common themes among metalloproteases.

Browner, M.F., Smith, W.W., Castelhano, A.L.

(1995) Biochemistry 34: 6602-6610

• PubMed: 7756291 
• Primary Citation of Related Structures:  
  1MMQ, 1MMP


• PubMed Abstract: 
  

Matrix metalloproteases are a family of enzymes that play critical roles in the physiological and pathological degradation of the extracellular matrix. These enzymes may be important therapeutic targets for the treatment of various diseases where tissue degradation is part of the pathology, such as cancer and arthritis. Matrilysin is the smallest member of this family of enzymes, all of which require zinc for catalytic activity. The first X-ray crystal structures of human matrilysin are presented. Inhibitors of metalloproteases are often characterized by the chemical group that interacts with the active site zinc of the protein. The structures of matrilysin complexed with hydroxamate (maximum resolution 1.9 A), carboxylate (maximum resolution 2.4 A), and sulfodiimine (maximum resolution 2.3 A) inhibitors are presented here and provide detailed information about how each functional group interacts with the catalytic zinc. Only the zinc-coordination group is variable in this series of inhibitors. Examination of these inhibitor-matrilysin complexes emphasizes the dominant role the zinc-coordinating group plays in determining the relative potencies of the inhibitors. The structures of these matrilysin-inhibitor complexes also provide a basis for comparing the catalytic mechanism of MMPs and other metalloproteins.

---

Organizational Affiliation: 

Molecular Structure Department, Syntex Discovery Research, Palo Alto, California 94303, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
MATRILYSIN	A	170	Homo sapiens	Mutation(s): 0  Gene Names: MMP7 (MPSL1, PUMP1) EC: 3.4.24.23
Find proteins for P09237 (Homo sapiens) Go to Gene View: MMP7 Go to UniProtKB:  P09237

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
SRS	A	4-METHYL-3-(9-OXO-1,8-DIAZA-TRICYCLO[10.6.1.0(13,18)]NONADECA-12(19),13(18),15,17-TETRAENE-10-CARBAMOYL)PENTA-METHYLSULFONEDIIMINE C25 H39 N5 O2 S MQEMTMGYPYUQLH-IRLDBZIGSA-N
ZN	A	ZINC ION Zn PTFCDOFLOPIGGS-UHFFFAOYSA-N
CA	A	CALCIUM ION Ca BHPQYMZQTOCNFJ-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
SRS	Ki: 4000 nM BINDINGMOAD
SRS	Ki: 4000 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.4 Å
• R-Value Work: 0.187 
• Space Group: P 3₁ 2 1

Unit Cell:

Length (Å)	Angle (°)
a = 62.100	α = 90.00
b = 62.100	β = 90.00
c = 87.400	γ = 120.00

Software Package:

Software Name	Purpose
MOSFLM	data reduction
X-PLOR	model building
X-PLOR	refinement
X-PLOR	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 1995-03-22 
• Released Date: 1996-04-03 
• Deposition Author(s): Browner, M.F., Smith, W.W., Castelhano, A.L.

Revision History 

• Version 1.0: 1996-04-03
  Type: Initial release
• Version 1.1: 2008-03-03
  Type: Version format compliance
• Version 1.2: 2011-07-13
  Type: Version format compliance